Categories AlphaGraphs, Consumer, Earnings
Key metrics from Kimberly-Clark’s (KMB) Q4 2024 earnings results
Kimberly-Clark Corporation (NYSE: KMB) reported its fourth quarter 2024 earnings results today.
Sales were $4.9 billion, down 0.8% from the same period last year. Organic sales were up 2.3%.
Net income attributable to Kimberly-Clark Corporation decreased 12.2% to $447 million while earnings per share dropped 10.7% to $1.34. Adjusted EPS decreased 0.7% to $1.50.
For fiscal year 2025, KMB expects adjusted EPS to grow at a mid-to-high single-digit rate on a constant-currency basis.
Prior performance
Listen to the conference calls as they happen. Don't miss a beat! With AlphaStreet Intelligence, you can listen to live calls and interviews as they happen, so you never have to worry about missing out on important information.
Most Popular
Key takeaways from JM Smucker’s (SJM) Q4 2025 earnings report
Shares of The J.M. Smucker Co. (NYSE: SJM) plunged 15% on Tuesday after the company delivered mixed results for the fourth quarter of 2025. While earnings came ahead of expectations,
J.M. Smucker (SJM) Q4 2025 Earnings: Key financials and quarterly highlights
The J.M. Smucker Co. (NYSE: SJM) reported its fourth quarter 2025 earnings results today. Net sales was $2.1 billion, down 3% year-over-year. Comparable net sales decreased 1%. Net loss was
Plus Therapeutics CEO: Lead candidate REYOBIQ demonstrates strong safety and efficacy in early trials
Plus Therapeutics (NASDAQ: PSTV) is a pharmaceutical company engaged in the development of targeted radiotherapeutics for difficult-to-treat cancers. Currently, it is advancing a pipeline of product candidates with lead programs
